Shattuck Labs, Inc.

NasdaqGS STTK

Shattuck Labs, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -0.72

Shattuck Labs, Inc. Price to Earnings Ratio (P/E) is -0.72 on January 14, 2025, a 84.66% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Shattuck Labs, Inc. 52-week high Price to Earnings Ratio (P/E) is -0.64 on November 22, 2024, which is 10.71% above the current Price to Earnings Ratio (P/E).
Shattuck Labs, Inc. 52-week low Price to Earnings Ratio (P/E) is -6.25 on May 06, 2024, which is -769.27% below the current Price to Earnings Ratio (P/E).
Shattuck Labs, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -2.95.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGS: STTK

Shattuck Labs, Inc.

CEO	Dr. Taylor H. Schreiber M.D., Ph.D.
IPO Date	Oct. 9, 2020
Location	United States
Headquarters	500 West 5th Street
Employees	75
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Key trends

Past 5 years